Symbols / BIAF Stock $2.02 -7.34% bioAffinity Technologies, Inc.

Healthcare • Diagnostics & Research • United States • NCM
BIAF (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Diagnostics & Research
CEO Ms. Maria Zannes J.D.
Exch · Country NCM · United States
Market Cap 9.09M
Enterprise Value 3.79M
Income -14.91M
Sales 6.16M
FCF (ttm) -4.93M
Book/sh 1.62
Cash/sh 1.44
Employees 57
Insider 10d —
IPO Sep 01, 2022
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -3.37
PEG —
P/S 1.47
P/B 1.25
P/C —
EV/EBITDA -0.38
EV/Sales 0.61
Quick Ratio 2.41
Current Ratio 2.60
Debt/Eq 15.95
LT Debt/Eq —
EPS (ttm) -8.66
EPS next Y -0.60
EPS Growth —
Revenue Growth -27.80%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2025-11-14
Earnings (prior) 2025-11-14
ROA -75.63%
ROE -3.02%
ROIC —
Gross Margin 31.41%
Oper. Margin -196.95%
Profit Margin -241.96%
Shs Outstand 4.50M
Shs Float 4.27M
Insider Own 3.26%
Instit Own 6.50%
Short Float 11.69%
Short Ratio 0.04
Short Interest 515.76K
52W High 15.00
vs 52W High -86.53%
52W Low 0.69
vs 52W Low 191.49%
Beta -1.19
Impl. Vol. —
Rel Volume 0.03
Avg Volume 9.05M
Volume 257.14K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $2.18
Price $2.02
Change -7.34%
About

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$2.02
Latest analyst target
3. DCF / Fair value
$-19.74
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.02
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-04-01 down Maxim Group Buy → Hold —
2024-07-23 init Maxim Group — → Buy $6
News
RSS: Latest BIAF news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-01-10 ZANNES MARIA Chief Executive Officer — 37,037 $0.00 $0
2025-01-10 GIRGENTI STEVEN Officer and Director — 14,814 $0.00 $0
2025-01-10 EDWARDS JAMES MICHAEL CPA Chief Financial Officer — 6,172 $0.00 $0
2025-01-10 ZANNES TIMOTHY PETER General Counsel — 8,641 $0.00 $0
2025-01-10 REVELES XAVIER TRINIDAD Chief Operating Officer — 21,604 $0.00 $0
2024-11-05 EDWARDS JAMES MICHAEL CPA Chief Financial Officer — 100,000 $0.00 $0
2024-07-01 KNIGHT PETER S Director — 33,784 $0.00 $0
2024-07-01 DIAMOND STUART Director — 33,784 $0.00 $0
2024-07-01 ZANNES MARIA Chief Executive Officer — 33,784 $0.00 $0
2024-07-01 ANDERSON ROBERT A Director — 33,784 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
6.11
-34.76%
9.36
+269.68%
2.53
+52627.44%
0.00
Operating Revenue
6.10
-34.76%
9.35
+272.55%
2.51
0.00
Cost Of Revenue
4.23
-29.36%
5.98
+243.70%
1.74
+372680.30%
0.00
Reconciled Cost Of Revenue
4.23
-29.36%
5.98
+243.70%
1.74
+372680.30%
0.00
Gross Profit
1.88
-44.32%
3.38
+326.79%
0.79
+18156.80%
0.00
Operating Expense
12.51
+1.42%
12.33
+40.70%
8.76
+118.28%
4.02
Research And Development
2.09
+17.18%
1.78
+3.38%
1.72
+13.15%
1.52
Selling General And Administration
9.91
-0.30%
9.94
+46.43%
6.79
+173.70%
2.48
General And Administrative Expense
—
—
—
—
Other Gand A
—
—
—
—
Total Expenses
16.73
-8.63%
18.32
+74.34%
10.51
+161.61%
4.02
Operating Income
-10.63
-18.69%
-8.95
-12.29%
-7.97
-98.78%
-4.01
Total Operating Income As Reported
-10.57
-18.08%
-8.95
-12.29%
-7.97
-98.78%
-4.01
EBITDA
-14.32
-71.87%
-8.33
-9.19%
-7.63
-36.02%
-5.61
Normalized EBITDA
-10.51
-26.12%
-8.33
-9.19%
-7.63
-31.06%
-5.82
Reconciled Depreciation
0.50
-16.64%
0.61
+142.65%
0.25
+2351.31%
0.01
EBIT
-14.82
-65.87%
-8.94
-13.41%
-7.88
-40.22%
-5.62
Total Unusual Items
-3.81
—
0.00
-100.00%
0.21
Total Unusual Items Excluding Goodwill
-3.81
—
0.00
-100.00%
0.21
Special Income Charges
—
—
0.00
-100.00%
0.21
Other Special Charges
—
—
—
-0.21
Net Income
-14.91
-64.93%
-9.04
-13.89%
-7.94
+2.66%
-8.15
Pretax Income
-14.87
-64.66%
-9.03
-14.05%
-7.92
+2.89%
-8.15
Net Non Operating Interest Income Expense
-0.02
+71.97%
-0.07
-188.07%
0.09
+103.42%
-2.49
Interest Expense Non Operating
0.04
-52.02%
0.09
+149.09%
0.04
-98.53%
2.53
Net Interest Income
-0.02
+71.97%
-0.07
-188.07%
0.09
+103.42%
-2.49
Interest Expense
0.04
-52.02%
0.09
+149.09%
0.04
-98.53%
2.53
Interest Income Non Operating
0.02
+32.79%
0.02
-85.58%
0.12
+161.48%
0.05
Interest Income
0.02
+32.79%
0.02
-85.58%
0.12
+161.48%
0.05
Other Income Expense
-4.27
-3311896.12%
0.00
+100.46%
-0.03
+98.32%
-1.65
Other Non Operating Income Expenses
-0.46
-358192.25%
0.00
+100.46%
-0.03
+98.51%
-1.87
Gain On Sale Of Security
-3.81
—
—
—
Tax Provision
0.04
+278.04%
0.01
-44.51%
0.02
+753.72%
0.00
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-14.91
-64.93%
-9.04
-13.89%
-7.94
+2.66%
-8.15
Net Income From Continuing Operation Net Minority Interest
-14.91
-64.93%
-9.04
-13.89%
-7.94
+2.66%
-8.15
Net Income From Continuing And Discontinued Operation
-14.91
-64.93%
-9.04
-13.89%
-7.94
+2.66%
-8.15
Net Income Continuous Operations
-14.91
-64.93%
-9.04
-13.89%
-7.94
+2.66%
-8.15
Normalized Income
-11.10
-22.78%
-9.04
-13.89%
-7.94
+5.13%
-8.37
Net Income Common Stockholders
-14.91
-64.93%
-9.04
-13.89%
-7.94
+2.66%
-8.15
Diluted EPS
-8.66
+61.51%
-22.50
+17.58%
-27.30
+49.72%
-54.30
Basic EPS
-8.66
+61.51%
-22.50
+17.58%
-27.30
+49.72%
-54.30
Basic Average Shares
1.72
+325.83%
0.40
+38.61%
0.29
+94.43%
0.15
Diluted Average Shares
1.72
+325.83%
0.40
+38.61%
0.29
+94.43%
0.15
Diluted NI Availto Com Stockholders
-14.91
-64.93%
-9.04
-13.89%
-7.94
+2.66%
-8.15
Depreciation Amortization Depletion Income Statement
0.50
-16.64%
0.61
+142.65%
0.25
+2351.31%
0.01
Depreciation And Amortization In Income Statement
0.50
-16.64%
0.61
+142.65%
0.25
+2351.31%
0.01
Line Item Trend 2023-12-31
Total Assets
8.22
Current Assets
3.97
Cash Cash Equivalents And Short Term Investments
2.82
Cash And Cash Equivalents
2.82
Receivables
0.81
Accounts Receivable
0.78
Other Receivables
0.03
Inventory
0.02
Prepaid Assets
0.17
Other Current Assets
0.15
Total Non Current Assets
4.25
Net PPE
1.99
Gross PPE
2.37
Accumulated Depreciation
-0.37
Properties
0.00
Buildings And Improvements
1.54
Machinery Furniture Equipment
0.17
Other Properties
2.18
Leases
0.01
Goodwill And Other Intangible Assets
2.24
Goodwill
1.40
Other Intangible Assets
0.83
Non Current Deferred Assets
—
Other Non Current Assets
0.02
Total Liabilities Net Minority Interest
3.37
Current Liabilities
2.25
Payables And Accrued Expenses
0.90
Payables
0.60
Accounts Payable
0.60
Current Accrued Expenses
0.29
Pensionand Other Post Retirement Benefit Plans Current
0.86
Current Debt And Capital Lease Obligation
0.46
Current Debt
—
Other Current Borrowings
—
Current Capital Lease Obligation
0.46
Current Deferred Liabilities
0.03
Current Deferred Revenue
0.03
Total Non Current Liabilities Net Minority Interest
1.12
Long Term Debt And Capital Lease Obligation
1.12
Long Term Debt
—
Long Term Capital Lease Obligation
1.12
Preferred Securities Outside Stock Equity
—
Stockholders Equity
4.86
Common Stock Equity
4.86
Capital Stock
0.07
Common Stock
0.07
Preferred Stock
0.00
Share Issued
0.31
Ordinary Shares Number
0.31
Treasury Shares Number
0.00
Additional Paid In Capital
49.39
Retained Earnings
-44.60
Total Equity Gross Minority Interest
4.86
Total Capitalization
4.86
Working Capital
1.72
Invested Capital
4.86
Total Debt
1.58
Net Debt
—
Capital Lease Obligations
1.58
Net Tangible Assets
2.62
Tangible Book Value
2.62
Interest Payable
—
Preferred Stock Equity
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-9.33
-28.41%
-7.26
-20.32%
-6.04
-48.32%
-4.07
Cash Flow From Continuing Operating Activities
-9.33
-28.41%
-7.26
-20.32%
-6.04
-48.32%
-4.07
Net Income From Continuing Operations
-14.91
-64.93%
-9.04
-13.89%
-7.94
+2.66%
-8.15
Depreciation Amortization Depletion
0.50
-16.64%
0.61
+142.65%
0.25
+2351.31%
0.01
Depreciation And Amortization
0.50
-16.64%
0.61
+142.65%
0.25
+2351.31%
0.01
Other Non Cash Items
—
—
—
3.92
Stock Based Compensation
0.67
-32.15%
0.99
+32.16%
0.75
+201.23%
0.25
Operating Gains Losses
3.81
—
—
-0.21
Gain Loss On Investment Securities
3.81
—
—
—
Change In Working Capital
0.59
+230.70%
0.18
-80.05%
0.90
+688.76%
0.11
Change In Receivables
0.60
+282.35%
-0.33
-205.19%
0.31
+3575.45%
-0.01
Change In Inventory
-0.03
-184.31%
-0.01
+29.51%
-0.01
-133.65%
-0.01
Change In Prepaid Assets
-0.09
+14.71%
-0.11
-149.25%
0.21
+143.51%
-0.49
Change In Payables And Accrued Expense
0.09
-85.14%
0.63
+81.70%
0.35
-44.08%
0.62
Change In Accrued Expense
0.32
+28.27%
0.25
-31.24%
0.36
-28.57%
0.51
Change In Payable
-0.23
-158.93%
0.38
+2737.89%
-0.01
-112.65%
0.11
Change In Account Payable
-0.23
-158.93%
0.38
+2737.89%
-0.01
-112.65%
0.11
Change In Other Working Capital
0.02
+303.10%
-0.01
-123.40%
0.04
—
Investing Cash Flow
-0.06
+23.41%
-0.08
+96.42%
-2.21
-904.33%
-0.22
Cash Flow From Continuing Investing Activities
-0.06
+23.41%
-0.08
+96.42%
-2.21
-904.33%
-0.22
Net PPE Purchase And Sale
-0.06
+23.41%
-0.08
-245.31%
-0.02
+89.59%
-0.22
Purchase Of PPE
-0.06
+23.41%
-0.08
-245.31%
-0.02
+89.59%
-0.22
Capital Expenditure
-0.06
+23.41%
-0.08
-245.31%
-0.02
+89.59%
-0.22
Net Business Purchase And Sale
—
0.00
+100.00%
-2.19
0.00
Purchase Of Business
—
0.00
+100.00%
-2.19
0.00
Financing Cash Flow
14.73
+161.82%
5.63
+1731.26%
-0.34
-102.41%
14.34
Cash Flow From Continuing Financing Activities
14.73
+161.82%
5.63
+1731.26%
-0.34
-102.41%
14.34
Net Issuance Payments Of Debt
-0.37
-118.34%
-0.17
+50.92%
-0.34
-159.06%
0.58
Issuance Of Debt
—
0.19
0.00
-100.00%
1.28
Repayment Of Debt
-0.37
-2.36%
-0.36
-4.70%
-0.34
+50.36%
-0.69
Long Term Debt Issuance
—
0.19
0.00
-100.00%
0.56
Long Term Debt Payments
-0.37
-2.36%
-0.36
-4.70%
-0.34
-27.78%
-0.27
Net Long Term Debt Issuance
-0.37
-118.34%
-0.17
+50.92%
-0.34
-220.98%
0.29
Short Term Debt Issuance
—
—
0.00
-100.00%
0.72
Short Term Debt Payments
—
—
0.00
+100.00%
-0.42
Net Short Term Debt Issuance
—
—
0.00
-100.00%
0.30
Net Common Stock Issuance
11.07
+97.26%
5.61
0.00
-100.00%
6.03
Proceeds From Stock Option Exercised
4.81
+232.91%
1.45
0.00
-100.00%
7.79
Net Other Financing Charges
-1.77
-40.42%
-1.26
—
-0.06
Changes In Cash
5.34
+411.40%
-1.72
+80.03%
-8.59
-185.47%
10.05
Beginning Cash Position
1.11
-60.83%
2.82
-75.28%
11.41
+738.85%
1.36
End Cash Position
6.45
+483.54%
1.11
-60.83%
2.82
-75.28%
11.41
Free Cash Flow
-9.39
-27.85%
-7.34
-21.17%
-6.06
-41.25%
-4.29
Interest Paid Supplemental Data
0.02
+32.79%
0.02
-52.57%
0.04
+1409.76%
0.00
Income Tax Paid Supplemental Data
0.04
+278.04%
0.01
-44.51%
0.02
-31.48%
0.03
Change In Interest Payable
—
0.00
0.00
-100.00%
0.44
Common Stock Issuance
11.07
+97.26%
5.61
0.00
-100.00%
6.03
Issuance Of Capital Stock
12.06
+114.89%
5.61
0.00
-100.00%
6.03
Net Preferred Stock Issuance
0.99
0.00
—
—
Preferred Stock Issuance
0.99
0.00
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category